Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Two-group Parallel, Positive-controlled Clinical Phase I Trial Comparing the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of CMAB818 and Lucentis® in Patients With Wet Age-related Macular Degeneration.

NCT04884399 is registered in ClinicalTrials.gov with Shanghai Biomabs Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04884399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04884399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Two-group Parallel, Positive-controlled Clinical Phase I Trial Comparing the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of CMAB818 and Lucentis® in Patients With Wet Age-related Macular Degeneration.
Lead sponsor
Shanghai Biomabs Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 3, 2021
Completion date
December 22, 2022
Enrollment
24 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

wet age-related macular degeneration